News & Views

November 22, 2023

Interview: Treehill Partners’ Ali Pashazadeh on How to Improve Clinical Trial Design

Posted By: TreehillPartners
In: Drug Development

From Ali Pashazadeh’s perspective, many trials fail because of how they are designed. And as the CEO of financial advisory firm Treehill Partners, he has a plan to solve that...

August 4, 2026

The Medicine Maker – Ali Pashazadeh on the Bottlenecks Slowing Drug Development

Posted By: TreehillPartners
In: Drug Development, Financing & Capital Markets, Leadership & Restructuring

July 21, 2026

The Medicine Maker Power List 2026 – Treehill Partners CEO Named Among the Most Influential Voices in Biopharma

Posted By: TreehillPartners
In: Strategy & Corporate Development

July 1, 2026

The Real Questions Behind the GLP-1 Boom

Posted By: TreehillPartners
In: Business Development & Licensing, Drug Development

June 19, 2026

The Drug Development Sector Is Failing Patients – And It Is Time We Asked Why

Posted By: TreehillPartners
In: Drug Development

June 16, 2026

Is Pharma at its “Nokia Moment” – Why the Pushpin of Global Drug Development Is Moving East

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring, Strategy & Corporate Development

November 20, 2023

Fosun Pharma USA and Treehill Partners launch joint efforts for capital investments in biopharma space

Posted By: TreehillPartners
In: Dealmaking

Fosun Pharma USA and Treehill Partners (Treehill) announce the formation of a jointly operating vehicle for investment in clinical-stage assets, further solidifying the relationship between the two companies...

June 1, 2026

The Cost of Coming Second in Clinical Trials

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

May 12, 2026

The Hidden Risks Behind Biotech Layoffs

Posted By: TreehillPartners
In: Leadership & Restructuring

March 25, 2026

Will Biotech Still Be Relevant in 2030? – Treehill on Onyx Newsroom

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

March 24, 2026

Biotechs Must Face Reality to Succeed in Today’s Funding Environment – Treehill Partners CEO in Biospace

Posted By: TreehillPartners
In: Financing & Capital Markets, Strategy & Corporate Development

March 5, 2026

JPM 2026 and Biotech’s New Reality – Treehill Partners CEO in Pharmaphorum

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

October 17, 2023

Treehill Partners launches novel service aimed at optimizing the biotech drug development process and fostering closer collaboration between key stakeholders

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

February 23, 2026

Scrip Asks – What Does 2026 Hold For Biopharma

Posted By: TreehillPartners
In: Leadership & Restructuring

February 19, 2026

Riding the Gene Therapy Rollercoaster into 2026 – Treehill CEO in Inside Precision Medicine

Posted By: TreehillPartners
In: Drug Development

February 9, 2026

Treehill Partners Featured in Cell & Gene Therapy Review’s 2026 Industry Predictions

Posted By: TreehillPartners
In: Drug Development

January 22, 2026

Oncology Investment – Treehill in Mergermarket

Posted By: TreehillPartners
In: Dealmaking

January 19, 2026

Scrip Asks – What Does 2026 Hold For Biopharma – Part 2

Posted By: TreehillPartners
In: Dealmaking, Drug Development

September 19, 2023

Korean Biotech on the Global Stage (Webinar Syneos Health / Treehill Partners)

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

Syneos One and Treehill Partners discuss how Korean biotech companies can optimize for the realities of today, highlighting alternate pathways to global markets and critical success factors...

January 13, 2026

Clinical Trial Partners: Sink or Swim (JPM 2026 Series, Episode 2) – Treehill Partners on Onyx Newsroom

Posted By: TreehillPartners
In: Drug Development

January 9, 2026

Global Shifts And Strategic Resilience Will Shape CGT In 2026 – Treehill in Cell & Gene

Posted By: TreehillPartners
In: Drug Development

January 9, 2026

Scrip Asks – What does 2026 hold for Biopharma? Part 1

Posted By: TreehillPartners
In: Dealmaking

November 20, 2025

London Life Sciences Week – In-Depth Interview

Posted By: TreehillPartners
In: Drug Development

November 19, 2025

Manufacturing Flexibility

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

July 20, 2023

Biotech Value Creation (Podcast Syneos Health / Treehill Partners)

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

The game continues to change in biotech as continued macroeconomic uncertainty has far reaching implications for the future of the biopharma ecosystem...

November 14, 2025

Treehill Partners Featured in FirstWord ExpertViews: The Convergence of Pharma and Biotech

Posted By: TreehillPartners
In: Strategy & Corporate Development

November 3, 2025

Pharma’s Path Through Industry Turbulence

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring

October 23, 2025

Neurology M&A – Treehill Quotes in Endpoints News

Posted By: TreehillPartners
In: Dealmaking

October 1, 2025

Treehill Partners CEO Featured in Newsweek Coverage of TrumpRx Initiative

Posted By: TreehillPartners
In: Drug Development, Strategy & Corporate Development

September 30, 2025

Treehill Partners Experts Featured in FirstWord Report on Biomarkers in Rare Disease Therapies

Posted By: TreehillPartners
In: Drug Development, Leadership & Restructuring, Strategy & Corporate Development

Subscribe to our mailings!

Scrip Asks – What does 2026 hold for Biopharma? Part 1

Scrip (Citeline) surveyed approximately 50 industry leaders for its annual “Scrip Asks” series — selected from over 330 submissions across the biopharma sector. Ali Pashazadeh,

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.